CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies

Download these slides from our live meeting series to review key strategies for integrating CAR T-cell therapy into your management of patients with hematologic malignancies.
Renier J. Brentjens, MD, PhD
Frederick L. Locke, MD
Noopur Raje, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.83 MB
Released: February 11, 2021

Acknowledgements

Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Kite Pharma

Related Content

Commentary on considerations affecting therapy recommendations for patients with myeloma in the evolving treatment landscape, from Clinical Care Options (CCO)

Brian G.M. Durie, MD
Program Director
Thomas G. Martin, MD Philippe Moreau, MD S. Vincent Rajkumar, MD Jesús F. San-Miguel, MD, PhD
Released: December 7, 2021

Commentary from Dr. Julie Vose on how to select therapy for patients with EBV-positive PTLD, from Clinical Care Options (CCO)

Julie M. Vose, MD, MBA Released: December 6, 2021

Downloadable PDF resource guide with key information and resources for optimal management of patients with T-cell lymphomas, from clinical care options (CCO)

Talha Khan, PharmD, BCOP Released: December 6, 2021

Interactive online tool with expert recommendations for assessing and managing adverse events associated with BTK inhibitors, from Clinical Care Options

Farrukh T. Awan, MD Christopher R. Flowers, MD, MS Nicole Lamanna, MD John P. Leonard, MD Julie M. Vose, MD, MBA Released: December 6, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue